Apeloa | Sustainability Performance
A Chinese pharmaceutical company focused on drug manufacturing and R&D.
1989
China
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10490
Overallⓘ#650
in Chinaⓘ#243
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Apeloa Pharmaceutical Co Ltd, Chinese major pharma intermediates/CDMO (sartan API supplier), has faced sustained US FDA enforcement scrutiny over alleged inadequate Chinese sartan API contamination disputes (NDMA carcinogenic impurity legacy affecting valsartan/losartan US generic supply chain), plus the contested 2024 sustained share price volatility affecting Chinese institutional shareholders amid USChina pharma decoupling pressure.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.